Lifesci Capital Has Strong Estimate for TARS FY2024 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Stock analysts at Lifesci Capital upped their FY2024 earnings estimates for Tarsus Pharmaceuticals in a research note issued on Thursday, November 14th. Lifesci Capital analyst C. Jubinville now expects that the company will post earnings per share of ($3.05) for the year, up from their prior forecast of ($3.89). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.41) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2024 earnings at ($0.55) EPS.

Other equities research analysts also recently issued reports about the company. The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Finally, William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock opened at $46.89 on Monday. The stock’s fifty day simple moving average is $38.41 and its 200 day simple moving average is $32.67. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.79 billion, a PE ratio of -12.31 and a beta of 1.00. Tarsus Pharmaceuticals has a 12 month low of $15.60 and a 12 month high of $52.99.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Tarsus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock worth $27,494,000 after purchasing an additional 62,555 shares in the last quarter. Barclays PLC boosted its stake in shares of Tarsus Pharmaceuticals by 345.9% during the 3rd quarter. Barclays PLC now owns 98,663 shares of the company’s stock worth $3,246,000 after buying an additional 76,538 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Tarsus Pharmaceuticals by 14.2% during the 3rd quarter. Wellington Management Group LLP now owns 145,347 shares of the company’s stock worth $4,780,000 after buying an additional 18,019 shares during the last quarter. Ikarian Capital LLC grew its holdings in shares of Tarsus Pharmaceuticals by 28.7% in the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock valued at $33,886,000 after acquiring an additional 230,000 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at about $763,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.